Start Your Risk-Free Subscription

Login

The Daily Biopharmaceutical News Source

Advanced Search

BioWorld-Insight-2003-03-24

Investors Edgy After Isis Failure; Genta's Drug Next Antisense Test

Investors Edgy After Isis Failure; Genta's Drug Next Antisense Test

By Randall Osborne

Monday, March 24, 2003

Last week's blowup of Isis Pharmaceuticals Inc.'s antisense drug, Affinitak, in a Phase III trial for non-small-cell lung cancer placed a question mark above that category of therapeutics, but nobody is flying the white flag of surrender yet. (BioWorld Financial Watch)

»

Login or register to post comments
Read more

Money Raised Year To Date

Monday, March 24, 2003

No Abstract

»

Login or register to post comments
Read more

Stock Winners and Losers For The Week

Monday, March 24, 2003

No Abstract

»

Login or register to post comments
Read more

Collaborations Between Biotechnology Companies And Universities/Non-Profit Institutions: Nov. 16, 2002 - March 19, 2003

Monday, March 24, 2003

No Abstract

»

Login or register to post comments
Read more

BioWorld Stock Report For Public Biotechnology Companies

Monday, March 24, 2003

No Abstract

»

Login or register to post comments
Read more

Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5476
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST

BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA

Part of Thompson Media Group LLC
Thompson.com | Sheshunoff.com | ASPratt.com | AHCMedia.com | BioWorld.com | CMEweb.com | ThePerformanceInstitute.org | ASMIweb.com

Editorial Guidelines

For Site License Discounts, please contact Customer Service at (800) 477-6307 or customerservice@bioworld.com.